Ekso Bionics (NASDAQ:EKSO) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a report released on Thursday morning. The firm issued a hold rating on the stock.

Several other equities analysts have also commented on EKSO. HC Wainwright reaffirmed a buy rating and issued a $10.00 price objective on shares of Ekso Bionics in a research report on Tuesday, July 30th. Lake Street Capital assumed coverage on shares of Ekso Bionics in a research report on Monday, June 24th. They issued a buy rating and a $2.50 price objective for the company.

Ekso Bionics Trading Up 0.7 %

NASDAQ EKSO opened at $0.90 on Thursday. The company’s 50-day moving average price is $1.10 and its 200-day moving average price is $1.36. The company has a current ratio of 2.42, a quick ratio of 2.11 and a debt-to-equity ratio of 0.36. The stock has a market cap of $16.30 million, a PE ratio of -0.92 and a beta of 1.51. Ekso Bionics has a 12 month low of $0.62 and a 12 month high of $3.13.

Ekso Bionics (NASDAQ:EKSO) last released its quarterly earnings data on Monday, July 29th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). The business had revenue of $4.95 million during the quarter, compared to analysts’ expectations of $5.34 million. Ekso Bionics had a negative return on equity of 92.08% and a negative net margin of 68.41%. During the same period last year, the company earned ($0.31) earnings per share. Equities research analysts forecast that Ekso Bionics will post -0.42 earnings per share for the current year.

Institutional Investors Weigh In On Ekso Bionics

A hedge fund recently raised its stake in Ekso Bionics stock. Kent Lake Capital LLC boosted its stake in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 596,050 shares of the company’s stock after acquiring an additional 454,892 shares during the quarter. Kent Lake Capital LLC owned 3.28% of Ekso Bionics worth $811,000 as of its most recent filing with the SEC. 6.42% of the stock is currently owned by institutional investors.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.